LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Stock List・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Closed

SectorHealthcare

5.04 0.8

Buy Sell

Overview

Share price change

24h

Current

Min

4.98

Max

5.17

Key metrics
By Trading Economics
Income	36M -3.7M
Sales	16M 66M
EPS	0.01
Profit margin	-5.67
Employees	416
EBITDA	57M 15M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+12.95% upside

Dividends
By Dow Jones
Next Earnings	10 Aug 2026

Market Stats
By TradingEconomics
Market Cap	354M 1.8B
Previous open	4.24
Previous close	5.04

News Sentiment

By Acuity

50%

161 / 344 Healthcare

Maravai LifeSciences Holdings Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

Related News

8 Jun 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 Jun 2026, 15:41 UTC

Major Market Movers

American Battery Shares Jump on Energy Department Victory

8 Jun 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 Jun 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 Jun 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 Jun 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8 Jun 2026, 21:57 UTC

Acquisitions, Mergers, Takeovers

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 Jun 2026, 21:56 UTC

Acquisitions, Mergers, Takeovers

Salesforce Agrees to Buy m3ter

8 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 Jun 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 Jun 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 Jun 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8 Jun 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 Jun 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 Jun 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 Jun 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 Jun 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 Jun 2026, 16:55 UTC

Acquisitions, Mergers, Takeovers

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 Jun 2026, 16:54 UTC

Acquisitions, Mergers, Takeovers

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 Jun 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 Jun 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 Jun 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8 Jun 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 Jun 2026, 16:03 UTC

Acquisitions, Mergers, Takeovers

Orange Bought Stake From Lorca

8 Jun 2026, 16:01 UTC

Acquisitions, Mergers, Takeovers

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 Jun 2026, 16:01 UTC

Acquisitions, Mergers, Takeovers

Orange Acquires 100% Ownership of MasOrange

8 Jun 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8 Jun 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 Jun 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 Jun 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

12.95% upside

12 Months Forecast

Average 5.67 USD 12.95%

High 6 USD

Low 5 USD

Based on 5 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Maravai LifeSciences Holdings Inc (Class A) - Dist in the past 3 months.

Sentiment

By Acuity

161 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.